<p><b>A & B.</b> C57BL/6 mice (5–6 mice/group) were immunized twice. The mice were s.c. injected with 5×10<sup>5</sup> EG-7 (<b>A</b>) or M05 (<b>B</b>). Tumor growth was monitored on the indicated days. * p<0.05, Ad-shA20-Mф immunization vs. Ad-con-Mф immunization. <b>C</b>. CD4<sup>−/−</sup> C57BL/6 or the wildtype littermates (5–6 mice/group) were immunized with OT-II-peptide-pulsed, Ad-shA20-transduced BMMфs twice followed by s.c. injection of 5×10<sup>5</sup> M05 tumor cells. Tumor occurrence and growth were monitored on the indicated days. **p<0.01, wild-type mice vs. CD4<sup>−/−</sup> mice. <b>D</b>. Transferred OT-II-specific immune pretection. In vitro primed OT-II T cells (5×10<sup>6</sup>) were transplanted into naïve RAG<sup>−/−</sup>C57BL/6 mice (5 mice/group) by retro-orbital injection following s.c injection of OVA-expressed B6SJ1003 tumor cells (6×10<sup>5</sup>). The transplantation of OT-II T cells was repeated one week later. One group of mice were transplanted with CMA-treated, Ad-shA20-transduced Mф-primed OT-II T cells. Tumor growth was monitored on the indicated days. *p<0.05, Ad-shA20-Mф-primed OT-II T cell transfer vs. Ad-con-Mф-primed OT-II T cell transfer, or Ad-shA20-Mф-primed OT-II T cell transfer vs. Ad-shA20-Mф-primed OT-II T cell+ CMT transfer. All the experiments were repeated with similar results.</p
